Search

MSK investigators have shown that a gene mutation linked to many kinds of cancer can also cause birth defects of the nervous system.

… Friday, February 26, 2016 Summary MSK investigators have shown that a mutation in a gene called PTEN that’s linked to many kinds of cancer can also cause birth defects of the nervous system. Their research unveils the mechanism by which the mutation affects cell shape and prevents cells from properly

Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis. Job loss can have devastating financial consequences, including increased risk of bankruptcy and debt. Victoria Blinder, MD, medical oncologist at Memorial Sloan Kettering, conducted a longitudinal study of a racially and ethnically diverse sample of employed women undergoing treatment for stage I-III breast cancer in New York City. For more information on this study, published in Health Affairs on February 6, 2017, and to speak with the study author, contact [email protected].

… Tuesday, February 7, 2017 Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis.  Job loss can have devastating financial consequences, including increased risk

As flu season ramps up amid the continuing uncertainty of the COVID-19 pandemic, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the risks and what precautions they could take to safeguard against the flu.

… Monday, November 16, 2020 As flu season ramps up amid the continuing uncertainty of the COVID-19 pandemic, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the risks and what precautions they could take to safeguard against the flu this year. The

Investigators have sequenced the genome of adenoid cystic carcinoma, a rare and deadly head and neck cancer. The work sets the stage for the sequencing of additional rare cancers at Memorial Sloan Kettering.

… Friday, May 24, 2013 Summary Investigators have sequenced the genome of adenoid cystic carcinoma, a rare and deadly head and neck cancer. The work sets the stage for the sequencing of additional rare cancers at Memorial Sloan Kettering. Since the completion of the Human Genome Project in 2003, many researchers

Sloan Kettering Institute scientists report new findings about a gene that helps regulate DNA methylation.

… Friday, April 9, 2021 The DNA in our genes contains the instructions needed to manufacture all of the proteins in our cells. These proteins, in turn, do the work that keeps our bodies functioning. Therefore, knowing how individual proteins get made can help us understand the causes of human disease,

For the first time, researchers have found an association between the makeup of the microorganisms in the body before a bone marrow transplant and a patient’s survival afterward.

… Sunday, December 2, 2018 Summary For the first time, researchers have found that having a healthy balance of microorganisms in the body before a bone marrow transplant is associated with higher survival rates after the transplant. Update: On February 27, 2020, Dr. Peled, Dr. van den Brink, and their

New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.

… Thursday, August 24, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient

A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email [email protected].

… Friday, June 10, 2016 A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on

Learn how to control weight gain during and after breast cancer treatment, from experts at MSK.

… Tuesday, August 12, 2025 Advances in breast cancer treatment mean more people than ever are surviving. There are nearly 4 million people living with breast cancer in the United States, and that number will continue to grow, thanks to lifesaving therapies. People diagnosed with breast cancer can help

The inaugural Kravis WiSE Symposium will take place virtually July 8-20, 2020. Each talk will be broadcast as part of the MSK Science Spotlight series, which is available via livestream and open to all.

… Tuesday, July 7, 2020 MSK has recently announced the establishment of the Marie-Josée Kravis Women in Science Endeavor ( WISE ) to provide financial and professional support to women scientists pursuing biomedical research at MSK, pledging its commitment to gender equity in science and paving the way